With Spark safe­ly tucked in­to Roche, its found­ing CEO is off to search for new ad­ven­tures

Spark Ther­a­peu­tics made his­to­ry at the FDA by win­ning the first-ever ap­proval for a gene ther­a­py, when the agency green­light­ed Lux­tur­na in late 2017. But the com­pa­ny and its found­ing CEO are prepar­ing to turn a new leaf.

Jeff Mar­raz­zo, Spark’s chief ex­ec­u­tive since its found­ing in 2013, will step down from his post on April 1, the biotech an­nounced Wednes­day morn­ing. COO Ron Philip was tapped to suc­ceed him af­ter a tran­si­tion pe­ri­od, and told End­points News he had planned to leave the com­pa­ny once its fu­ture with Roche was se­cure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER